Provides relative to biomarker testing. (gov sig) (OR SEE FISC NOTE GF EX)

Senate Bill 169 amends the Louisiana Insurance Code provisions governing health coverage for biomarker testing by clarifying the definition of clinical utility and restricting the conditions insurers may impose on coverage. The bill modifies R.S. 22:1028.5(D) and adds new provisions at R.S. 22:1028.5(B)(4) and (F). Specifically, the legislation establishes that clinical utility is deemed demonstrated when a biomarker test meets any one of the criteria previously listed in existing law, thereby providing an explicit standard for what constitutes sufficient demonstration of clinical utility. The bill further prohibits health coverage plans from conditioning coverage of a biomarker test on laboratory classifications or credentialing standards that are unrelated to the actual performance of the test itself. Additionally, the statute creates a conflict resolution mechanism by providing that if any provisions conflict with R.S. 22:1028.3 (the cancer screening biomarker testing statute), the provisions of the biomarker testing statute shall prevail.

Health insurers offering coverage in Louisiana and patients seeking biomarker testing are directly affected by these changes. Insurers will no longer be able to deny or limit coverage for clinically useful biomarker tests based on which laboratory performs the test or what credentials that laboratory holds, so long as the laboratory can adequately perform the test itself. Patients will benefit from more streamlined access to necessary biomarker testing without facing coverage denials rooted in laboratory classification schemes, and they will avoid the practical burden of obtaining multiple biopsies or samples when a single test could accomplish the diagnostic objective. The change also resolves inconsistencies between two separate insurance code provisions dealing with genetic testing for cancer risk and biomarker testing of existing conditions, harmonizing the legal framework governing both areas.

This legislation operates within the existing Louisiana insurance regulatory framework established in R.S. 22:1028.3 and R.S. 22:1028.5. Prior law already required coverage for biomarker testing when clinical utility was demonstrated, but the precise definition of that standard and the permissible bases for denying coverage created ambiguity. The bill clarifies that clinical utility follows the existing enumerated criteria in the statute and eliminates what the legislature evidently viewed as an improper workaround whereby insurers could avoid coverage obligations by focusing on laboratory characteristics rather than test performance. The statutory hierarchy established in new subsection (F) ensures that the specialized biomarker testing provisions take precedence over any broader or conflicting provisions in the cancer screening statute, creating a unified legal approach to genetic and biomarker testing coverage under Louisiana insurance law.